BMI1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16740731	1.00	20/20
SCHEMBL16740784	1.00	20/20
SCHEMBL16740791	1.00	20/20
SCHEMBL16740882	1.00	20/20
SCHEMBL16740836	0.79	20/20
SCHEMBL16740727	1.00	19/20
SCHEMBL16740752	1.00	19/20
SCHEMBL16740846	1.00	19/20
SCHEMBL16740867	1.00	19/20
SCHEMBL16740722	1.00	18/20
SCHEMBL16740741	1.00	18/20
SCHEMBL16740777	1.00	18/20
SCHEMBL16740788	1.00	18/20
SCHEMBL16740793	1.00	18/20
SCHEMBL16740745	1.00	17/20
SCHEMBL16740766	0.80	17/20
SCHEMBL16550242	0.75	17/20
SCHEMBL16740362	0.75	17/20
SCHEMBL16540549	0.74	17/20
SCHEMBL16739707	0.73	17/20

Clinical trials — most relevant to BMI1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer	PHASE1/PHASE2	RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes	PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Tazemetostat and Palbociclib With CPX-351for R/R AML	PHASE1	RECRUITING
Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma	nan	UNKNOWN
Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.	nan	UNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Exploratory Study of Rectal Mucus for Diagnosing Disease	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer	nan	ACTIVE_NOT_RECRUITING
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases	nan	RECRUITING
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BMI1 binder may also engage these)

Protein	Name	Similarity
Q5R8L2	—	1.000	Q5R8L2 →
Q32KX7	—	1.000	Q32KX7 →
Q9TST0	—	1.000	Q9TST0 →
P25916	—	1.000	P25916 →
Q5SDR3	—	0.999	Q5SDR3 →
Q8JIR0	—	0.998	Q8JIR0 →
Q7T3E6	—	0.998	Q7T3E6 →
Q91648	—	0.997	Q91648 →
Q640D5	—	0.992	Q640D5 →
P23798	—	0.990	P23798 →
P35227	—	0.989	P35227 →
Q86SE9	—	0.978	Q86SE9 →
A0JN86	—	0.974	A0JN86 →
P22448	—	0.974	P22448 →
P18514	—	0.972	P18514 →
Q9W6B3	—	0.971	Q9W6B3 →
Q9BSM1	—	0.970	Q9BSM1 →
Q3UK78	—	0.970	Q3UK78 →
Q7ZYZ7	—	0.970	Q7ZYZ7 →
A4IID4	—	0.968	A4IID4 →
RARB	Retinoic acid receptor beta	0.968	landscape →
Q9BWT3	—	0.968	Q9BWT3 →
Q2YDF9	—	0.967	Q2YDF9 →
P11416	—	0.967	P11416 →
PRKD1	Serine/threonine-protein kinase D1	0.966	landscape →
Q8BPM2	—	0.966	Q8BPM2 →
Q1JPS1	—	0.965	Q1JPS1 →
A6NI28	—	0.965	A6NI28 →
PRKD3	Serine/threonine-protein kinase D3	0.965	landscape →
PI4KB	Phosphatidylinositol 4-kinase beta	0.965	landscape →